JACC. Heart failure最新文献

{"title":"Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure Patients","authors":"Paul Gautier MD, MSc , Meyer Elbaz MD, PhD , Julien Bezin PharmD, PhD , Clément Delmas MD, PhD , Miloud Cherbi MD , Frédéric Bouisset MD, PhD , Cécile Vindis PhD , Axel Renoux MSc , Margaux Lafaurie PharmD, PhD , François Montastruc MD, PhD","doi":"10.1016/j.jchf.2025.02.017","DOIUrl":"10.1016/j.jchf.2025.02.017","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 5","pages":"Pages 870-872"},"PeriodicalIF":10.3,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143907976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revisiting ICD Therapy for Primary Prevention","authors":"Ilan Goldenberg MD , Justin A. Ezekowitz MBBCh, MSc , Javed Butler MD, MPH","doi":"10.1016/j.jchf.2025.01.031","DOIUrl":"10.1016/j.jchf.2025.01.031","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 5","pages":"Page 880"},"PeriodicalIF":10.3,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143907980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Atrial Fibrillation Ablation for Heart Failure With Preserved Ejection Fraction","authors":"Pieter Martens MD, MSc, PhD ,&nbsp;Silvio Nunes Augusto Jr ,&nbsp;Jonas Erzeel MD ,&nbsp;Laurent Pison MD, PhD ,&nbsp;Wilfried Mullens MD, PhD ,&nbsp;W.H. Wilson Tang MD","doi":"10.1016/j.jchf.2025.01.029","DOIUrl":"10.1016/j.jchf.2025.01.029","url":null,"abstract":"<div><h3>Background</h3><div>Atrial fibrillation (AF) ablation is Class I recommendation in selected heart failure (HF) patients with reduced ejection fraction; less is known in heart failure with preserved ejection fraction (HFpEF).</div></div><div><h3>Objectives</h3><div>The aim of this study was to investigate the effects of AF ablation in patients with HFpEF.</div></div><div><h3>Methods</h3><div>The CABANA (Catheter Ablation vs Antiarrhythmic Drug Therapy for Atrial Fibrillation) trial randomized patients with cardiovascular risk factors for stroke to AF ablation vs drug therapy. The presence of a high likelihood of HFpEF at enrollment was determined by a modified H₂FPEF score of ≥6. Treatment effects of baseline HFpEF likelihood on the AF ablation for death and cardiovascular admission, AF recurrence, and functional status were assessed.</div></div><div><h3>Results</h3><div>A total of 1,763 patients were included in the analysis. A high modified H₂FPEF score (55% of the entire cohort) resulted in a significant treatment effect modulation (<em>P</em> for interaction = 0.027), with a lower risk for cardiovascular hospitalization or death in patients with a high likelihood of HFpEF (HR: 0.82 [95% CI: 0.69-0.98]; <em>P =</em> 0.025), but not in patients without (HR: 1.00 [95% CI: 0.82-1.22]; <em>P =</em> 0.987). Although patients with a high likelihood of HFpEF were at a higher risk for AF recurrence, the greatest treatment effect of AF ablation on AF recurrence was observed in patients with a high likelihood of HFpEF (<em>P</em> for interaction = 0.035). In a sensitivity analysis in a subset of patients with echocardiographic evidence of HFpEF (n = 225), a similar treatment interaction was found.</div></div><div><h3>Conclusions</h3><div>In patients undergoing AF ablation, the presence of underlying HFpEF (either by HFpEF probability or defined by echocardiography) was associated with a larger benefit with AF ablation on clinical outcome, AF recurrence, and functional status. (Catheter Ablation vs Antiarrhythmic Drug Therapy for Atrial Fibrillation [CABANA]; <span><span>NCT00911508</span><svg><path></path></svg></span>)</div></div>","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 5","pages":"Pages 785-794"},"PeriodicalIF":10.3,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143907527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The 2023 American College of Cardiology Advanced Heart Failure Staffing Survey","authors":"Maya Guglin MD, PhD ,&nbsp;Amrut V. Ambardekar MD ,&nbsp;Anju Bhardwaj MD ,&nbsp;Lauren Beth Cooper MD ,&nbsp;Ersilia M. DeFilippis MD ,&nbsp;Nadia Fida MD ,&nbsp;Shelley Hall MD ,&nbsp;Dustin Hillerson MD ,&nbsp;Onyedika J. Ilonze MD ,&nbsp;Anuradha Lala MD ,&nbsp;Nikhil Narang MD ,&nbsp;Megan N. Pelter MD ,&nbsp;Navin Rajagopalan MD ,&nbsp;Bhavadharini Ramu MD ,&nbsp;Anne K. Rzeszut","doi":"10.1016/j.jchf.2025.01.022","DOIUrl":"10.1016/j.jchf.2025.01.022","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 5","pages":"Pages 840-845"},"PeriodicalIF":10.3,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143907532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient Preference Should Take Precedence in Status 2 Listing for Heart Transplantation","authors":"Colby Salerno DO,&nbsp;Sounok Sen MD","doi":"10.1016/j.jchf.2025.02.018","DOIUrl":"10.1016/j.jchf.2025.02.018","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 5","pages":"Pages 855-856"},"PeriodicalIF":10.3,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143908258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current Landscape of Therapies for Transthyretin Amyloid Cardiomyopathy","authors":"Jan M. Griffin MD ,&nbsp;Justin L. Grodin MD, MPH ,&nbsp;Frederick L. Ruberg MD ,&nbsp;Ahmad Masri MD, MS ,&nbsp;Mazen Hanna MD ,&nbsp;Mathew S. Maurer MD","doi":"10.1016/j.jchf.2025.03.017","DOIUrl":"10.1016/j.jchf.2025.03.017","url":null,"abstract":"<div><div>Transthyretin amyloid cardiomyopathy (ATTR-CM) is an infiltrative cardiomyopathy that results from myocardial deposition of misfolded transthyretin (TTR) protein. The biology of amyloid formation has been elucidated resulting in several effective therapeutic strategies. Accordingly, the therapeutic landscape for ATTR-CM is rapidly evolving, with multiple disease-modifying therapies (DMTs) approved and others anticipated to be imminently available. Currently, DMT strategies involve either stabilization of TTR, thereby inhibiting misfolding, or reduction of hepatic TTR production, and antibodies (“depleters”) that facilitate amyloid fibril removal are under development. In this review, available evidence is synthesized and expert experience provided to assist clinicians in the complex navigation of treatment selection and the role of advanced therapies (heart transplantation and left ventricular assist device), as well as to identify key areas for future research.</div></div>","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 5","pages":"Pages 685-694"},"PeriodicalIF":10.3,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143907035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glucagon-Like Peptide 1 Receptor Agonist Is Associated With Improved Survival in Overweight Heart Failure Patients","authors":"Patric Karlström MD, PhD ,&nbsp;Aldina Pivodic PhD ,&nbsp;Michael Fu MD, PhD","doi":"10.1016/j.jchf.2024.12.004","DOIUrl":"10.1016/j.jchf.2024.12.004","url":null,"abstract":"<div><h3>Background</h3><div>Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have shown improved symptomatic relieving and functional capacity in patients with heart failure (HF) with preserved ejection fraction and obesity.</div></div><div><h3>Objectives</h3><div>The purpose of this study was to evaluate the effect of GLP-1RA on outcome in patients with HF.</div></div><div><h3>Methods</h3><div>A retrospective analysis was performed based on the Swedish HF Registry since 2007 among patients with a body mass index (BMI) &gt;25 kg/m² to assess whether GLP-1RA treatment was associated with reduced mortality in patients with HF.</div></div><div><h3>Results</h3><div>In the overall cohort, 34,247 patients were not treated with GLP-1RA, and 808 patients were. In patients treated with GLP-1RA, 96.3% had diabetes mellitus. Treatment with GLP-1RA showed a statistically significant association with reduced all-cause (adjusted HR [aHR]: 0.75 [95% CI: 0.60-0.94]; <em>P =</em> 0.013) and cardiovascular (CV) mortality (aHR: 0.52 [95% CI: 0.35-0.77]; <em>P =</em> 0.0010) compared with those not receiving GLP-1RA within 2 years after index registration. In a 1:1 propensity score matched cohort, there was no significant association between GLP-1RA and all-cause mortality (aHR: 0.79 [95% CI: 0.59-1.06]; <em>P =</em> 0.11), but there was with CV mortality (aHR: 0.53 [95% CI: 0.32-0.87]; <em>P =</em> 0.012). GLP-1RA–associated risk reduction in CV death was more pronounced in patients with a BMI &gt;30 kg/m² and appears to be greater in individuals with an ejection fraction ≤40% compared with &gt;40%.</div></div><div><h3>Conclusions</h3><div>This nationwide real-world study shows that patients with HF who received GLP-1RA have a significant reduction in CV mortality, which is particularly pronounced in overweight and obese patients with reduced ejection fraction.</div></div>","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 5","pages":"Pages 754-766"},"PeriodicalIF":10.3,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143633807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influence of Obesity on Invasive Hemodynamics and Prognosis in Patients With Heart Failure","authors":"Benjamin Lautrup Hansen MD ,&nbsp;Tania Deis MD ,&nbsp;Johan E. Larsson MD ,&nbsp;Mads Ersbøll MD, PhD ,&nbsp;Kasper Rossing MD, DMSci ,&nbsp;Morten Schou MD, PhD, DMSci ,&nbsp;Hoong Sern Lim MD, PhD, DMSci ,&nbsp;Finn Gustafsson MD, PhD, DMSci","doi":"10.1016/j.jchf.2024.12.009","DOIUrl":"10.1016/j.jchf.2024.12.009","url":null,"abstract":"<div><h3>Background</h3><div>Previous studies have suggested that obesity may cause heart failure with preserved left ventricular ejection and report strong association between body mass index (BMI) and invasive hemodynamics. However, sparse information exists in patients who have heart failure with reduced ejection fraction (HFrEF).</div></div><div><h3>Objectives</h3><div>This study aimed to investigate associations between BMI and invasive hemodynamics in patients with HFrEF and the influence of obesity on clinical outcomes.</div></div><div><h3>Methods</h3><div>Referred patients with HFrEF evaluated for advanced heart failure were studied. All patients had right heart catheterization performed. Obesity was defined as BMI ≥30 kg/m². Clinical events included death, heart transplantation, and durable left ventricular assist device implantation.</div></div><div><h3>Results</h3><div>The study population comprises 578 patients with a mean age of 52 ± 13 years and BMI of 26 ± 5 kg/m². Patients with obesity (BMI range: 30-45 kg/m²) counted 126 (22%) and had significantly higher cardiac output and slightly higher central venous pressure compared to patients without obesity. Cardiac output increased by 89 mL/min per 1-U increase in BMI. Vascular resistances were significantly inversely related to BMI. Pulmonary arterial pressure and pulmonary capillary wedge pressure were not associated with BMI. In patients with obesity, symptoms seem to be dissociated from filling pressures and cardiac index, whereas a clear association is observed in patients without. Obesity did not predict survival over a median follow-up of 5.9 years (Q1-Q3: 2.0-10.1 years).</div></div><div><h3>Conclusions</h3><div>In patients with HFrEF, BMI and CO correlate significantly. Symptoms and hemodynamics appear dissociated in patients with obesity. Finally, survival in patients with obesity did not differ from those without.</div></div>","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 5","pages":"Pages 725-736"},"PeriodicalIF":10.3,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143673239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Extracoronary Calcification and Incident Heart Failure in the Multiethnic Study of Atherosclerosis (MESA)","authors":"Sandeep Brar MD ,&nbsp;Rahul Goli MD ,&nbsp;Joshua P. Barrios PhD ,&nbsp;Michael J. Blaha MD, MPH ,&nbsp;Sina Kianoush MD, MPH ,&nbsp;Mark J. Pletcher MD, MPH ,&nbsp;Sarah O. Nomura PhD ,&nbsp;Michael Y. Tsai PhD ,&nbsp;Rong Duan MS ,&nbsp;Matthew J. Budoff MD ,&nbsp;Moyses Szklo MD, DrPH ,&nbsp;Geoffrey H. Tison MD, MPH","doi":"10.1016/j.jchf.2024.12.007","DOIUrl":"10.1016/j.jchf.2024.12.007","url":null,"abstract":"<div><h3>Background</h3><div>Extracoronary calcification (ECC) is a prevalent cardiovascular risk factor.</div></div><div><h3>Objectives</h3><div>The aim of this study was to examine the association between ECC and heart failure (HF), including heart failure with preserved ejection fraction (HFpEF).</div></div><div><h3>Methods</h3><div>MESA (Multi-Ethnic Study of Atherosclerosis) participants with computed tomographic imaging at baseline for calcification of the aortic valve, aortic root, mitral valve, and thoracic aorta were included. ECC score was calculated by rescaling Agatston scores from 0 to 1 for each ECC site and summing the rescaled scores. Multivariable Cox proportional hazards regression was performed to examine the association between ECC quartiles and incident HF.</div></div><div><h3>Results</h3><div>Of all MESA participants, 3,617 (53.1%) and 3,192 (46.9%) had ECC scores of 0 and &gt;0, respectively. During a mean follow-up period of 12.9 ± 4.2 years, 358 HF events were observed, 179 HF with reduced ejection fraction and 135 HFpEF. After controlling for demographics and risk factors, the highest ECC quartile (compared with the lowest quartile) had 1.7-fold greater hazard of incident HF (adjusted HR: 1.72 [95% CI: 1.16-2.55]; <em>P =</em> 0.007), though this was attenuated to borderline significance after additional adjustment for coronary artery calcification. In contrast for HFpEF, the highest ECC quartile (compared with the lowest quartile) remained independently and statistically significantly associated with 3-fold greater hazard of incident HFpEF (adjusted HR: 3.09 [95% CI: 1.45-6.60]; <em>P =</em> 0.003) after full adjustment, including for coronary artery calcification.</div></div><div><h3>Conclusions</h3><div>ECC is associated with increased risk for HF, in particular HFpEF. If this finding is confirmed in other studies, ECC could help improve traditional risk factor estimation and clinical risk assessments for HF and HFpEF.</div></div>","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 5","pages":"Pages 740-751"},"PeriodicalIF":10.3,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143719398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sodium-Glucose Cotransporter 2 Inhibitors in Tafamidis-Treated Transthyretin Amyloid Cardiomyopathy","authors":"Kuan-Yu Chi MD ,&nbsp;Dimitrios Varrias MD ,&nbsp;Pawel Borkowski MD ,&nbsp;Anita Osabutey MD, MPH ,&nbsp;Junmin Song MD ,&nbsp;Cho-Han Chiang MD ,&nbsp;Yu-Cheng Chang MD ,&nbsp;Pei-Lun Lee MD ,&nbsp;Yu Chang MD ,&nbsp;Robert T. Faillace MD ,&nbsp;Ulrich Jorde MD ,&nbsp;Omar Saeed MD ,&nbsp;Jose Gonzalez-Costello MD ,&nbsp;Shivank Madan MD, MHA ,&nbsp;Snehal R. Patel MD","doi":"10.1016/j.jchf.2025.01.025","DOIUrl":"10.1016/j.jchf.2025.01.025","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 5","pages":"Pages 863-866"},"PeriodicalIF":10.3,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143907523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}